Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice

[1]  A. Awasthi,et al.  Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions , 2023, Frontiers in Immunology.

[2]  P. K. Garg,et al.  A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern , 2022, PLoS pathogens.

[3]  R. Webby,et al.  Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents , 2022, Nature.

[4]  J. Zahradník,et al.  Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.

[5]  A. Sigal,et al.  Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection , 2022, Nature Communications.

[6]  R. Bull,et al.  Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission , 2022, Reviews in medical virology.

[7]  O. Pybus,et al.  Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.

[8]  A. Awasthi,et al.  Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis , 2022, bioRxiv.

[9]  B. Clotet,et al.  Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice , 2022, Frontiers in Microbiology.

[10]  A. Sette,et al.  SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents , 2022, Cell Reports Medicine.

[11]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.

[12]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[13]  Larissa B. Thackray,et al.  SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters , 2022, Nature.

[14]  P. K. Garg,et al.  Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months , 2022, eBioMedicine.

[15]  S. Madhi,et al.  SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.

[16]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[17]  P. Ho,et al.  Off balance: Interferons in COVID-19 lung infections , 2021, EBioMedicine.

[18]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[19]  A. Awasthi,et al.  High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity , 2021, Science advances.

[20]  A. Walls,et al.  Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants , 2021, bioRxiv.

[21]  Xinwen Chen,et al.  SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury , 2021, bioRxiv.

[22]  A. Awasthi,et al.  EGFR-HIF1α signaling positively regulates the differentiation of IL-9 producing T helper cells , 2021, Nature Communications.

[23]  R. Goel,et al.  Gefitinib Results in Robust Host-Directed Immunity Against Salmonella Infection Through Proteo-Metabolomic Reprogramming , 2021, Frontiers in Immunology.

[24]  T. Welte,et al.  COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses , 2021, Immunity.

[25]  L. Weinstock,et al.  Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome , 2020, International Journal of Infectious Diseases.

[26]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[27]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[28]  D. Lewis,et al.  COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives , 2020, Nature Reviews Cardiology.

[29]  D. Matthews,et al.  Neuropilin-1 is a host factor for SARS-CoV-2 infection , 2020, Science.

[30]  A. Ortiz,et al.  Kidney disease and electrolytes in COVID-19: more than meets the eye , 2020, Clinical kidney journal.

[31]  H. Yen,et al.  Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020, Nature.

[32]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[33]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[34]  M. Neurath.  COVID-19 and immunomodulation in IBD , 2020, Gut.

[35]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[36]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[38]  Andrea Marzi,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[39]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[41]  Rajiv K. Saxena,et al.  Evidence of CD1d pathway of lipid antigen presentation in mouse primary lung epithelial cells and its up-regulation upon Mycobacterium bovis BCG infection , 2018, PloS one.

[42]  A. Awasthi,et al.  Transcription factor Foxo1 is essential for IL-9 induction in T helper cells , 2017, Nature Communications.

[43]  Rajiv K. Saxena,et al.  Lipid antigen presentation through CD1d pathway in mouse lung epithelial cells, macrophages and dendritic cells and its suppression by poly-dispersed single-walled carbon nanotubes. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[44]  T. Giese,et al.  Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. , 2009, The Journal of allergy and clinical immunology.